ZA200409558B - Method for the protection of endothelial and epithelial cells during chemotherapy. - Google Patents

Description

METHOD FOR THE PROTECTION OF ENDOTHELIAL AND EPITHELIAL CELLS

DURING CHEMOTHERAPY

. Field of the invention

The invention relates to the field use of radiation therapy and/or chemotherapy. More specifically, the invention relates to a method for assuaging side effects associated with such treatment.

State of the art

Allogeneic stem cell transplantation (SCT) is a well established method for the treat- ment of hematological neoplasias and an increasing variety of other malignant disor- ders. SCT mainly consists of two sequential steps: The pretransplant conditioning, classically consisting of total body irradiation (TBI) and chemotherapy, leading to minimal residual disease and the immunosuppression of the recipient as the first step, and the transfer of allogeneic stem cells that should finally provide the cure as oo the second step. However, due to disparities in major (MHC) and minor (mHAg) his- tocompatibility antigens, severe inflammatory reactions, including acute graft-versus- host disease (GVHD), can occur in different phases post transplant. Based on studies by the inventors’ and several other investigators®® it is widely accepted that condi- tioning contributes via non-specific inflammation to these transplant-related compli- cations (TRC). In addition, a direct toxicity of especially TBI has been demon- strated *® This has led to a variety of alternative conditioning regimens currently un- der investigation. In addition, new pre transplant therapies allow the extension of treatment protocols and the patients” selection. One compound of these novel condi- tioning concepts is fludarabine, a non-myeloablative immunosuppressant that had originally been used for the treatment of chronic lymphatic leukemia.? Fludarabine in combination with e.g. BCNU and melphalan, cyclophosphamide or other agents can replace TBI or is used together with dose reduced TBI regimens.”® The clinical data , obtained so far argue for comparably low side effects and a hematopoetic and im- mune cell specificity of fludarabine.’ However, the influence of this compound on non-hematopoetic cells like endothelial and epithelial cells has not been subject to investigation yet.

Virtually all TRC are associated with endothelial dysfunction and damage.” The in- ' ventors and others have shown that the endothelium is a target of pre-transplant conditioning in vitro and in vivo. lonizing radiation induces programmed cell death (apoptosis) in endothelial cells.” At the same time the endothelium is activated in terms of adhesion molecule expression leading to increased leukocyte-endothelial interactions as a prerequisite for inflammatory processes.'>1® These effects are sig- nificantly enhanced by bacterial endotoxin (lipopolysaccharide, LPS) that might translocate through damaged mucosal barriers from the gastrointestinal tract." In addition, LPS has been shown to increase the antigenicity of endothelial cells to- wards allogeneic CD8+ cytotoxic T lymphocytes. '®

Clinical results with fludarabine containing reduced intensity conditioning (RIC) regi- mens obtained so far show a clear downregulation of conditioning-related toxicity without affecting immune reconstitution. The incidence of acute GvHD in patients receiving RIC is comparable or even less than in those patients receiving the classi- cal conditioning regimen.?® However, reports on equally severe or even increased late effects like osteonecrosis, ?’ pulmonal complications, and more cases of chronic

GvHD? clearly demonstrate the potential for serious side effects associated with flu- darabine treatment.

Summary of the invention

The invention is based on the discovery that fludarabine activates and damages en- dothelial and epithelial cells. The activation of the cells leads to damage in the treat- ment situation where fludarabine is used, e.g., when treating malignancies using . SCT. The epithelial and endothelial cells can be protected from this activation and damage by treatment with defibrotide. This treatment may be concomitant or defi- ‘ brotide may be given before treatment with fludarabine or thereafter.

Abbreviations and definitions

SCT: Haematopoetic stem cell transplantation.

Immunosupp ressant: substance that down-regulates the immune response of a sub- ject upon adrministration. Immunosuppressants are used in suppressing the immune system of patients undergoing stem cell therapy. Examples of immunosuppressants include fludarabine, cyclophosphamide, BCNU, cyclosporin, sirolimus, tacrolimus and melphalan. Preferred within the context of this application is fludarabine (also known } as 2-fluoro-9—p-D-arabinofuranosyladenine).

Protective oli godeoxyribonucleotide: shall mean, within the context of this application, both oligodeoxyribonucleotides as defined in US patent 5,646,268 and polydeoxyri- bonucleotide s as defined in US 5,223,609, which are incorporated by reference herein in thei r entirety.

US patent 5, 646,268 discloses a process for producing an oligodeoxyribonucleotide having the fo-llowing physico-chemical and chemical characteristics:

Molecular weaight: 4000-10000 h: <10

A+T/C+G* 1.100-1.455

A+G/IC+T= 0.800 —1.160

Specific rotation : +30° - + 48° *base molar ratio h= hyperchromicity parameter

A process for producing such an oligodeoxyribonucleotide comprises: precipitating 0.8M sodium acetate aqueous solutions of polydeoxyribonucleotide so- dium salts att 20° C by addition of an alkyl alcohol selected from the group consisting of ethyl, propyl and isopropyl alcohol.

US patent 5,223,609 discloses a defibrotide which fulfills certain pharmacological and therape utical properties and is therefore particularly suitable, if the nucleotide fractions forrning it are in stoichiometrical agreement with the following polydeoxyri- bonucleotidiac formula of random sequence: ) P15, (dAP)12. 24, (dGP)10-20, (dTP)13-26, (dCP)10-20 wherein

P=phosphor-ic radical dAp=deoxyadenylic monomer dGp=deoxyguanylic monomer dTp=deoxythymidylic monomer dCp=deoxycytidylic monomer ) The Defibrotide corresponding to this formula moreover shows the following chemico-physical properties: electrophoresis=homogeneous anodic mobility; extinc- tion coefficient, E 1m’ at 260 +1 nm=220 + 10; extinction ratio, Eas /E2e0 =0.45 + 0.04; coefficient of molar extinction (referred to phosphorous), e(P)=7.750 + 500; ro- tatory power [a]p?® =53 ° + 6; reversible hyperchromicity, indicated as % in native

DNA, h=15 +5.

A preferred protective oligodeoxyribonucleotide is Defibrotide (CAS Registry Number: 83712-60-1), a polynucleotide well known to the person skilled in the art, which nor- mally identifies a polydeoxyribonucleotide obtained by extraction (US 3,770,720 and

US 3,899,481) from animal and/or vegetable tissue; this polydeoxyribonucleotide is normally used in the form of a salt of an alkali metal, generally sodium, and usually ~ hasa molecular weight of approximately 45-50 kDa. Defibrotide is used principally for its antithrombotic activity (US 3,829,567) although it may be used in different applica- tions, such as, for example, the treatment of acute renal insufficiency (US 4,694,134) and the treatment of acute myocardial ischaemia (US 4,693,995). United States pat- ents US 4,985,552 and US 5,223,609 describe a process for the production of defi- brotide which enables a product to be obtained which has constant and well defined physico-chemical characteristics and is also free from any undesired side-effects.

Detailed description of the invention

The invention relates to a method for the treatment of a patient undergoing treatment with an immunosuppressant, comprising the step of administering an effective dose of a protective oligodeoxyribonucleotide to the patient. The treatment with an immu- nosuppressant preferably occurs during SCT. The immunosuppressant is preferably . selected from the group comprising antimetabolites (e.g., 5-fluorouracil (5-FU), methotrexate (MTX), fludarabine, anti-microtubule agents (e.g., vincristine, vinblas- tine, taxanes (such as paclitaxel and docetaxel)), alkylating agents (e.g., cyclophas- phamide, melphalan, bischloroethylnitrosurea (BCNU)), platinum agents (e.g., cis-

pl atin (also termed cDDP), carboplatin, oxaliplatin, JM-216, Cl1-973), anthracyclines (e.g., doxorubicin, daunorubicin), antibiotic agents including mitomycin-C, topoi- somerase inhibitors (e.g., etoposide, camptothecin), cyclosporin, tacrolimus, siro- ’ lirmus, and other cytotoxic agents that act to suppress the immune system. A review off such agents that are frequently used in the therapy of malignancies may be found ira Gonzales et al., Alergol. Immunol. Clin. 15, 161-181, 2000, which is incorporated herein by reference. Preferred immunosuppressants are nucleosides (i.e. the gly- cosides resulting from the removal of the phosphate group from a nucleotide), as for instance fludarabine which, by the way, is the preferred immunosuppressant for the p urposes of the present invention.

T he protective oligodeoxyribonucleotide may be administered concurrently, simulta- raeously, or together with the immunosuppressant. A preferred combination is the si- mnultaneous gavage of defibrotide and fludarabine.

T he step of administering the protective oligodeoxyribonucleotide preferably occurs concurrently, concomitantly, simultaneously, after or before the gavage of the immu- mosuppressant to the patient. { n a preferred embodiment of the invention, the step of administering the protective oligodeoxyribonucleotide occurs after gavage of the immunosuppressant to the pa- t ient. In a further preferred embodiment, the time delay between step of administering the protective and the gavage of the immunosuppressant to the patient is about one our to about two weeks. The time delay between the step of administering the pro- fective and the gavage of the immunosuppressant to the patient is preferably about £wo days to about seven days.

In another preferred embodiment of the invention, the step of administering the pro- +tective oligodeoxyribonucleotide occurs before gavage of the immunosuppressant to the patient. Preferably, the time difference between step of administering the protec- ) tive and the gavage of the immunosuppressant to the patient is about one hour to about two weeks. More preferably, the time difference between step of administering the protective and the gavage of the immunosuppressant to the patient is about two hours to about two days.

The preferred protective oligodeoxyribonucleotide is defibrotide, however, other sub- stances as mentioned above as protective oligonucleotides may be used. The fol- lowing embodiments define preferred doses for defibrotide; however, similar doses may be used when using a protective oligodeoxyribonucleotide which is not defi- brotide. The optimal dose for any protective oligodeoxyribonucleotide will be deter- mined by the attending physician. The experiments described below show the pro- tective effects of defibrotide. The effective dose determined in such experiments may be used as a guide for determining an effective dose for treatment.

The defibrotide is preferably administered orally or is injected intravenously.

The preferred dose of of defibrotide is chosen so as to reach a blood level of about 100 pg/mL to 0.1 pg/mL. More preferably, the dose of defibrotide is chosen so as to reach a blood level of about 10 pg/mL to about 100 pg/mL. Most preferably, the dose of defibrotide is chosen so as to reach a blood level of about 100 pg/mL.

In a preferred embodiment of the invention, the dose of defibrotide administered is about 100 mg/kg body weight of the patient to about 0.01 mg/kg body weight. Pref- erably, the dose of defibrotide administered is about 20 mg/kg body weight of the pa- tient to about 0.1 mg/kg body weight. More preferably, the dose of defibrotide ad- ministered is about 15 mg/kg body weight of the patient to about 1 mg/kg body weight. More preferably, a daily dosage of about 12 mg to about 14 mg per Kg. of body weight of the patient is administered. Most preferably, the dose of defibrotide administered is about 12 mg/kg body weight of the patient.

Preferably, administration of a protective oligodeoxyribonucleotide according to the invention according to the invention is able to protect endothelial cells and epithelial cells from the effects of the immunosuppressant. The immunosuppressant preferably activates epithelial cells and endothelial cells and induces apoptosis therein. Thus, in a preferred embodiment, the protecting olideoxynucleotide protects epithelial and/or endothelial cells from apoptosis and/or activation by the immunosuppressant. The immunosuppressant is preferably fludarabine. The protective oligodeoxyribonucieo- . tide is preferably defibrotide.

The activation includes enhanced expression of ICAM-1 and of MHC class | mole- cules. The enhancement of expression is preferably substantial. Further preferably,

the immunosuppressant induces a pro-inflammatory activation of endothelial cells and/or of epithelial cells in a patient. The cells are preferably human microvascular endothelial cells (HMEC) and/or dermal and/or alveolar epithelial cells. The damage preferably occurs when the patient's endothelial and/or epithelial cells have been ex- posed to the immunosuppressant for about 1 hour to about 1 week or more. More : preferably, said damage occurs when said cells have been exposed for about 5 hours to about 72 hours. Even more preferably, the duration of such exposure is between 20 hours and 72 hours. Most preferably, the duration of such exposure is more than 48 hours.

The treatment with the immunosupressant preferably occurs during haematopoetic stem cell transplantation. The haematopoetic stem cell transplantation is preferably allogeneic haematopoetic stem cell transplantation.

The invention also relates to a pharmaceutical composition comprising at least a protective oligodeoxynucleotide, for the treatment of a patient in need thereof, which patient is being treated with an immunosuppressant. The administration of said pharmaceutical composition alleviates or protects from side effects caused by the immunosuppressant or by the immunosuppressant and a transplant. The transplant is preferably a bone marrow or haematopoetic stem cell transplant. More preferably, the transplant is an allogeneic bone marrow or haematopoetic stem cell transplant.

The side effects are preferably related to endothial and/or epithelial cells and/or tis- sues of the patient. Preferably, said side effects involve apoptosis of said cells, and/or activation of said cells. The activation preferably comprises enhanced expres- sion of MHC class | molecules and/or of intercellular adhesion molecule 1 (ICAM-1).

The side effects damages human microvascular endothelial cells (HMEC) as well as, preferably, dermal and alveolar epithelial cell lines after 48 hours of culture, when used in pharmacologically relevant concentrations (range: 10 pg/mL to 1 pg/mL). . The side effects generally include damages to target tissues of transplant related complications and stimulated allogeneic immune responses.

The side effects preferably include significant upregulation of the intercellular adhe- sion molecule 1 (ICAM-1) and MHC class | molecules in endothelial cells and/or pei- thelial cells of the patient, particularly in alveolar endothelial cells. The side effects further include a a pro-inflammatory activation of microvascular endothelial cells. The side effects further preferably include enhanced lysis of such cells by by allogeneic } MHC class | restricted cytotoxic T lymphocytes derived from the transplant.

Adminstration of the protective oligodeoxynucleotide preferably protects against im- munosuppressant-induced side effects, including apoptosis and alloactivation.

The pharmaceutical compositions comprising the immunosuppressant of the present invention can be formulated with techniques, excipients and vehicles of conventional and well known type, for the administration both orally and by injection, particularly by intravenous route. The dosages of active ingredient in the compositions according to the present invention ranges between 50 and 1500 mg for unitary dose, whereas to attain the desired results the daily administration of 10 to 40 mg/kg is suggested.

Methods for the preparation defibrotide may be found in US 4,985,552 and US 5,223,609, which patents are incorporated hereby in their entirety by reference.

The invention also relates to a pharmaceutical composition containing a therapeuti- cally effective dose of an immunosuppressant and of a protective oligodeoxyribonu- cleotide. The immunosuppressant is preferably fludarabine. protective oligodeoxyri- bonucleotide is preferably defibrotide.

Brief description of the Figures

Fig 1: Fludarabine induces programmed cell death in human micorvascular en- dothelial cells (HMEC). HMEC were either left untreated or incubated with 2-fluoro- 9-p-D-arabinofuranosyladenine (hereinafter referred to as F-Ara, the metabolized form of fludarabine) in descending concentrations for 48 hours and subjected to flow cytometric analysis (A) or microscopic DAPI stain analysis. A: Contour plots of the : side scatter (SSC) image (x-axis) of propidium iodide (P1)-negative cells plotted against the forward scatter image (y-axis) as a parameter for cellular granularity ver- sus cell size. B: Quantitative fluorescence microscopy analysis of DAPI-stained en- dothelial cells. Results are given in % apoptotic HMEC (% apoptotic cells) + standard deviation (out of n= 10 microscopic fields with an average of 70 cells per field). Rep- resentatives of at least five independent experiments are shown. *: p<0.001 of un- treated control versus F-Ara (10 ug/ml) treated cells.

Fig 2: Defibrotide (D) inhibits F-Ara-induced apoptosis in HMEC, evidence for ] an intracellular antagonism. F-Ara: 10 pg/mL. D: 100 ug/mL. Flow cytometric analysis of the SSC-image of Pl-negative cells. A: reproducible induction of apoptosis by F-Ara. B: Dose-dependent inhibition of F-Ara-induced apoptosis by D. C: left plot: incubation of HMEC with F-Ara for 1 hour, subsequent incubation with D for 48 hours after washing. Right plot: incubation of HMEC with D for 1 hour, subsequent incuba- tion with F-Ara for 48 hours after washing. For experimental details see legend to Fig 1 and Materials and Methods. Shown is one representative out of three independent experiments.

Fig 3: F-Ara induces apoptosis in keratinocytes and alveolar epithelial cells, but not in gut or bronchial epithelial cells; protective effect of Defibrotide. F-

Ara: 10 pg/mL. D: 100 pg/mL. Flow cytometric analysis of the SSC-image of PlI- negative cells (Fig 3 A) and DAPI-stain analysis of apoptotic cells (Fig 3 B). Results are given in mean % apoptotic cells + standard deviation out of three different ex- periments. HaCaT: human keratinocyte cell line. SW 480: gut epithelial cells line. A 549: lung carcinoma cell line from the alveolar epithelium. BEAS-2B: bronchial epithelial cell line. Primary bronchial epithelial cells have been derived from a bron- choscopic brush procedure. Fig 3 A: *: p=0.005 of F-Ara- versus F-Ara+D treated

HaCaT cells. **; p=0.116 of F-Ara versus F-Ara+D treated A 549 cells. § : no apopto- sis induction. Fig 3 B: +: p=0.026 of F-Ara- versus F-Ara+D treated HaCaT cells. ++: p=0.001 of F-Ara versus F-Ara+D treated A 549 cells. For experimental details see legend to Fig 1 and Materials and Methods. Three representative experiments are summarized for each cell line.

Fig 4: Defibrotide (D) does not interfere with the anti-leukaemic and the anti- . PBMC effect of F-Ara. F-Ara: 10 pg/mL. D: 100 ug/mL. A: Propidium iodide staining of primary acute myeloid leukemia (AML) cells derived from a patient in blast Crisis (70 % blasts of total PBMC count). Results are given in mean % vitality of three inde- pendent experiments. *: p=0.008 of Control- versus F-Ara-treated AML cells. B: Flow cytometric analysis of the SSC-image of Pl-negative PBMC. Shown is one repre- sentative out of five independent experiments with different blood donors.

Fig 5: F-Ara induces ICAM-1 expression on HMEC, protective effect off Defi- brotide (D). Flow cytometric analysis of ICAM-1 positive cells. HMEC were eit her left ) untreated or incubated with F-Ara (10 pg/mL, or descending concentrations i-n B) in the presence or absence of descending concentrations of D. A: Histogram plot of

ICAM-1 expression from a representative experiment. Dotted line: Back ground staining (nil control); thin line: ICAM-1 expression of untreated control cells; thi ck line:

ICAM-1 expression of F-Ara-treated cells. B: Dose-dependent induction of | CAM-1 expression by F-Ara. Summary of three independent experiments. Results ares given as mean % ICAM-1 positive cells standard deviation. *: p=0.075 of F-Ara- versus untreated control cells. C: Dose-dependent inhibition of F-Ara-induced ICAMA-1 ex- pression by Defibrotide (D). Results are given as mean % ICAM-1 positive cells + standard deviation. **; p=0.004 of F-Ara- versus F-Ara+D-treated HMEC.

Fig 6: F-Ara increases the allogenicity of HMEC for CD8-positive cytoteoxic T- lymphocytes (CTL), protective effect of Defibrotide. A: PBMC were stirnulated with irradiated HMEC in the presence of interleukin 2 (50 U/mL) for 7 days a nd sub- jected to a S1Cr release assay with untreated (Control) and F-Ara (10 ug/mlL)—treated

HMEC (24 hour-incubation) as target cells. autolog. B-LCL: autologous (effector)

EBV-transformed B-lymphoblastoid cells. K 562: target cells for natural kill er (NK) cells. Results are given as % specific lysis as described in Materials and Methods. +: % specific lysis of F-Ara-treated HMEC in the presence of anti-MHC cla: ss | an- tibody w6/32. E/T ratio: effector/target ratio. B: Downregulation of F-Ara-induced allo- genicity of HMEC towards CD8-positive CTL by Defibrotide (D). CD8-positivea PBMC have been negatively selected (non-CD8+-cell-depleted) by magnetic bead separa- tion. For experimental details see legend to Fig 6 A.

Fig 7: F-Ara decreases the allogenicity of HMEC for NK cells, enhancemment of lysis by blockade of MHC class I. NK cells have been negatively selected ( non-NK- cell-depleted) by magnetic bead separation and stimulated with irradiated HMEC in the presence of IL-2 (50 U/mL) for 4 days and subsequently subjected to a SCr re- lease assay as described for Fig 6. Table below the graph: Flow cytometric analysis of the effector cell population pre and post stimulation with HMEC. NK cells were characterized as CD3-/CD16+CD56+. +: % specific lysis of K 562 cells at E/T ratio of 20:1.

Table 1: Anti-endothelial CTL elicit a T.1-like phenotype. a cc

LR Li ;

ELISA for the production of interferon gamma (IFN-y) and interleukin 4 (IL-4) in the supernatants of stimulated effector cells (7 days, irradiated HMEC, 50 U/mL IL-2).

PBMC were either left unseparated or negatively selected for CD8+ T cells as given for the experiments in Fig 6. Results are given as mean pg/mL cytokine + standard deviation of 3 independent experiments.

Examples - METHODS

Cell culture and reagents

The human dermal microvascular endothelial cell line CDC/EU.-HMEC-1 (further re- ferred to as HMEC) was kindly provided by the centres for Disease Control and Pre- vention (Atlanta, Georgia, USA) and has been established as previously described."

HMEC were cultured in MCDB131 medium, supplemented with 15% fetal calf serum (FCS), 1 pg/mL hydrocortisone (Sigma, Deisenhofen, Germany), 10 ng/mL epidermal growth factor (Collaborative Biochemical Products, Bedford, MA, USA) and antibiot- ics. All cell culture reagents have been purchased by Gibco BRL (Karlsruhe, Ger- many) unless stated otherwise. 2-Fluoroadenine 9-beta-D-arabinofuranoside (F-Ara) was obtained from Sigma, Deisenhofen, Germany, Defibrotide vials were obtained from Prociclide™, Crinos, Como, Italy.

Apoptosis assays

An established method for detecting apoptosis in human endothelial cells was per- formed as previously described? using flow cytometry (FACScan™ and CellQuest™ software, Becton Dickinson, Heidelberg, Germany). Endothelial and epithelial cells were either left untreated or incubated with F-Ara in descending concentrations (range: 10ug/mL to 0.1 pg/ml) in the presence or absence of Dexfibrotide for 48 hours. Afterwards, cells were washed in PBS/10% FCS and stained with the necrosis detecting dye propidium iodide (Pl, 0.2 pg/mL, Sigma, Deisenho-fen, Germany).

Apoptotic cells were identified by a Pl-negative staining and by a characteristic side : scatter image distinct from that of non-apoptotic cells. At least three experiments per cell type have been performed.

An alternative method for the detection of apoptosis used microscopic analysis of

DNA fluorescence labeled cells. 1x10%/plate endothelial cells were s eeded in 35mm petri dishes (Nunc, Wiesbaden, Germany). These cells were treated as given above and subsequently fixed with Methanol/Acetone (1:1) for 2 minutes, wvashed once in

PBS and stained with 4,6-Diamidino-2-phenylindole (DAP!) (0.5 pg/ mL, Sigma, De- isenhofen, Germany), dissolved in 20% Glycerin/PBS. Samples wewme mounted and subjected to microscopic analysis. Nuclear condensation as revealed by DAPI stain- ing in the absence of trypan blue uptake is considered characteristic of apoptosis as opposed to necrosis.?! The quantitative analysis included counting the number of apoptotic relative to all identifiable cells from at least 10 microscopi c fields, with an average of 70 cells per field.

For the sake of the clarity of the manuscript DAP! stain results are o nly displayed for the experiments with endothelial cells and HaCaT as well as A 549 cells.

Cell surface analyses

Cell surface expression of ICAM-1 (Becton Dickinson/Pharmingen, Heidelberg, Ger- many) and MHC class | (w6/32, hybridoma supernatant, ATCC, Manzassas, VA, USA) molecules on HMEC was assessed by the indirect immunofluores cence technique and subsequent flow cytometry using the FACScan™ flow cytome ter and the Cell-

Quest™ analysis program (Becton Dickinson, Heidelberg, Germany). Endothelial cells were treated as given and after incubation harvested with tryps in/EDTA (Gibco), washed once in cold PBS/ 10% FCS and incubated 1 hour on ice= with 5 pg/mL of anti-adhesion molecule MoAbs. Cells were washed again and incutbated with a goat anti-mouse 1gG-FITC conjugated antibody F(ab)y fragment (Dako , Hamburg, Ger- many) for 45 minutes on ice. Cells were then washed in PBS/ 10%% FCS and sub- jected to analysis. Viability of the cells was determined by concurr ent propidium io- dide (0.2 uyg/mL, Sigma, Deisenhofen, Germany) staining. Omitting of the first anti-

body served as a negative control to detect unspecific fluorescence. This approach, instead of using isotype control antibodies, was justified by previous observations that endothelial cells lack Fc receptors. Therefore, a non-specific binding of anti- bodies through their Fc portion could be excluded.

Allostimulation of peripheral blood cells with HMEC

Peripheral blood mononuclear cells (PBMC) were derived from heparinized (Novo

Nordisk, Mainz, Germany) blood of healthy human volunteers or buffy coats from the

Bavarian Red Cross according to a standard protocol using Ficoll hypaque (Pharma- cia, Freiburg, Germany) density gradient centrifugation. Cells were then stimulated in a ratio of 1:1 and 2:1 with irradiated (20 Gy) HMEC for 7 days in the presence of In- terleukin 2 (50 U/mL) and 10% human AB serum (Sigma, Deisenhofen, Germany).

Alternatively, PBMC were selected for CD8+ T cells and natural killer (NK) cells using cell isolation kits according to the manufactuer’s instructions (MACS™, Miltenyi Bio- tech, Bergisch-Gladbach, Germany) based on the deletion of non CD8+ and non NK cells, respectively. Stimulation of the selected cells was identical to that of whole

PBMC cultures, except for NK cells which were stimulated for only 3 days.

Cytotoxicity assay

T cell- or NK-cell mediated cytotoxicity was assessed according to a well established protocol, 2® using a 4h *'Cr radioisotope assay. HMEC that had either been left un- treated or incubated with F-Ara (10pg/mL) overnight were used as target cells, to be labeled 0.4 mCi Na2?'CrO4 for 2 hours. After 3 washing steps, target cells were ad- justed to 10* cells/mL and coincubated with PBMC, CD8+ or NK effector cells at de- scending effector to target ratios for another 4 hours. Supematants were transfered. to dry scintillation plates and counted in a y-counter (all from Canberra Packard,

Darmstadt, Germany). Autologous (effector) B-Lymphoblastoid cell lines (B-LCL) and

K562 as NK sensitive cells were taken as additional control targets. The percentage of specific lysis was calculated as: [(experimental release - spontaneous re- lease)/(maximal release - spontaneous release)] x 100. Spontaneous release in all experiments was always below 20%.

Enzyme linked immunosorbent assays (ELISA)

The ELISA for the detection of Interleukin 4 (IL-4, T.2 response) and Interferon y (IFN+y, Tc1 response), IL-1 and IL-10 in the supernatants of allogeneic effector T cells (see below) were performed exactly according to the manufacturer’s kit instructions (R&D Systems, Minneapolis, MN, USA). . Statistical analysis

The significance of differences between experimental values was assessed by means of the Student's t-test.

Example 1

F-Ara induces apoptosis (programmed cell death) in human microvascular en- dothelial cells (HMEC)

In order to assess the influence of F-Ara on the viability of cultured human endothe- lial cells, HMEC were incubated with descending pharmacologically relevant concen- trations (10 pg/mL to 0.1 pg/mL) of 2-Fluoroadenine 9-beta-D-arabinofuranoside as the metabolized form of fludarabine. The median intracellular level of the active (cy- totoxic) fludarabine triphosphate in target cells is 20 uM, representing a concentration 5.8 pg/mL (medac SCHERING, manufacturers’s instructions). After 48 hours of incu- bation HMEC were subjected to apoptosis assays using the detection of cellular granularity of propidium iodide negative cells (side scatter (SSC) image in flow cy- tometry) and microscopic analyses of DAPI-stained cells, respectively. Independent of the assays system, Fig 1 A and B clearly demonstrate that F-Ara causes apoptosis in HMEC in concentrations of 10 and 5 pg/mL, whereas 1 pg/mL was no longer ef- fective. The critical threshold of the cytotoxicity of F-Ara was between 2 and 3 pg/mL.

Apoptosis by F-Ara was already detectable after 24h, though to a lesser extent (data not shown).

Example 2 : Defibrotide protects HMEC from the F-Ara induced apoptosis

HMEC had either been left untreated or treated with F-Ara in the presence or ab- : sence of varying concentrations of Defibrotide (100 pug/mbL to 0.1 pg/mL) and as- sessed for programmed cell death after 48 hours using flow cytometric analyses of the SSC image as described for Fig 1 A. Fig 2 A (mid contour plot) shows that Defi- brotide alone as a second control did not influence endothelial cell viability. The apoptotic effect of F-Ara is reproduced in Fig 2 A (right contour plot), whereas Fig 2 B shows a dose-dependent protection of F-Ara induced cell death by Defibrotide. In or- der to exclude unspecific artifical extracellular interaction of F-Ara and Defibrotide in vitro HMEC were pretreated with Defibrotide for 1 hour and subsequently, after 3 washing steps, incubated with F-Ara for another 48 hours and vice versa. Fig2C (right contour plot) reveales that pretreatment of HMEC for 1 hour was sufficient to protect cells from F-Ara induced apoptosis. Similarly, pretreatment of HMEC with F-

Ara for 1 hour (Fig 2 C, left contour plot) and subsequent incubation with Defibrotide did not lead to endothelial programmed cell death.

Example 3

Effect of F-Ara on different epithelial cell lines, protective effect of Defibrotide

Skin, the gastrointestinal tract (GIT) and most likely the lung are among the primary targets of GvHD. Therefore, it was reasonable to test the influence of F-Ara on cell lines derived from these organs. Cells from keratinocyte (HaCaT), GIT (SW 480), alveolar (A549) and bronchial epithelial (BEAS-2B) cell lines as well as primary bron- chial epithelial cells were incubated with F-Ara (10 pg/mL) as given for Figs 1and 2 and assayed in flow cytometric apoptosis analyses 48 hours post treatment. Fig 3 A summarizes that gut and bronchial epithelial cells appeared to be resistant to the apoptotic stimuli of F-Ara, whereas keratinocytes (HaCaT) and alveolar epithelial cells (A549) showed signs of apoptosis, as determined by flow cytometry of the SSC image (34.0 [+1.0] % apoptotic cells for HaCaT and 42.9 [26.7] % for A549, respec- tively). Again, the protective potential of Defibrotide (100 pg/mL) was assessed. Ha-

CaT (4.3 [3.0] %) and A 549 (5.4 [+2.9] %) cells were completely protected from programmed cell death after cotreatment with F-Ara and Defibrotide Fig. 3 A, in- serted bar graphs). To confirm these results, DAPI-stain apoptosis assays were per- formed for HaCAT (Fig 3 B, left columns) and A 548 cells (Fig. 3 B, right columns).

As shown for endothelial cells, Defibrotide alone did not influence the number of apoptotic cells in either cell line (data not shown). . Example 4

Defibrotide does not interfere with the anti-leukaemic and anti-PBMC effect of

F-Ara

Next to its desirable protective capacity for endothelial and epithelial cells against F-

Ara induced apoptosis it was important to investigate whether Defibrotide would also interfere with the anti-leukaemic properties of F-Ara. To address this question, pri- mary peripheral blood derived acute myeloid leukaemic (AML) cells with a blast amount of 70 % were thawed, kept in culture for 24 hours and subsequently treated with F-Ara in the presence or absence of Defibrotide for another 48 hours. Fig4 A demonstrates that already almost 50 % of the cells died spontaneously of necrotic cell death. However, F-Ara induced cell death in up to 80 % of the cells. In contrast to its effect on endothelial and epithelial cells, Defibrotide was not able to protect the

AML cells from the F-Ara mediated toxicity. It is of note that Fig 4 A describes % Vi- tality of the cells, not % apoptotic cells, due to the fact that F-Ara directly caused ne- crosis, rather than apoptosis in AML cells. This could be observed after as early as 24 hours of incubation. Still, Fig 4 A clearly shows that Defibrotide does not interfere with the desirable toxicity of F-Ara against leukaemic cells. We next asked whether

Defibrotide might modulate the effect of F-Ara against normal haematopoetic cells and performed apoptosis assays (SSC-image) with PBMC from normal human blood donors. As could be learned from a representative experiment depicted in Fig 4 B, F-

Ara induced apoptosis in 40.1 % of the cells as compared to 5.1 % apoptotic cells in the untreated control. Again, Defibrotide did not interfere with the apoptotic activity of

F-Ara against PBMC (43.1 % apoptotic cells), suggesting that the immunosuppress- sive properties of F-Ara are not harmed by cotreatment with Defibrotide.

Example 5

F-Ara upregulates intercellular adhesion molecule 1 (ICAM-1) on HMEC with an- tagonistic effects of Defibrotide

Based on previous observations that pretransplant conditioning not only damages, but also leads to proinflammatory activation of endothelial cells in terms of adhesion molecule induction,’ we next investigated the expression of ICAM-1 under the influ- ence of F-Ara. As depicted in Fig 5 A and B, flow cytometric analyses demonstrated that F-Ara, after 24 hours of incubation, significantly enhances expression on HMEC . in a dose-dependent manner similar to that observed for apoptosis induction. Con- centrations down to 1 pg/mL of F-Ara were effective in inducing ICAM-1. We next asked whether Defibrotide would also be functional as an antagonist of F-Ara in this experimental setting. HMEC were treated with F-Ara as given and incubated in the presence or absence of descending concentrations of Defibrotide. Fig 5 C summa- rizes 3 independent experiments showing that Defibrotide in fact antagonized the F-

Ara induced ICAM-1 expression in concentrations of 100 pg/mL and 10 pg/mL. Itis of note that Defibrotide alone did not activate endothelial cells, the ICAM-1 expresssion remained unchanged with every concentration tested (data not shown).

Since a proinflammatory activation of target cells is often associated with increased expression of major histocompatibility antigens (MHC) class | and Il, we did further flow cytometric analyses for these antigens after incubation with F-Ara in various concentrations for 24 hours. Despite its well described immunosuppressive proper- ties, F-Ara surprisingly induced MHC class | molecules on HMEC dose-dependently (1.5 fold induction of mean fluorescence intensity at 10 pg/mL, 1.3 fold induction at 5 pg/mL), whereas MHC class il remained unchanged (data not shown).

Example 6

F-Ara increases the antigenicity of endothelial cells towards allogeneic periph- eral blood cells, protection by Defibrotide

The induction of MHC class | molecules on HMEC by F-Ara prompted us to examine whether F-Ara would also enhance the capacity of HMEC to stimulate allocytotoxic responses. Peripheral blood mononuclear cells (PBMC) as effectors were either de- rived from heparinized blood of healthy human volunteers of from buffy coat prepara- tions, stimulated with irradiated (20 Gy) HMEC in the presence of 50 U/mL interleukin 2 (IL-2) for 7 days and subsequently subjected to a standard Cr release assay (for details see Materials and Methods). At day —1 fresh HMEC as targets were either left unstimulated or incubated with F-Ara (10pg/mL) in the presence or absence of an anti-MHC class | neutralizing antibody (w6/32). Autologous effector Epstein-Barr vi- rus transformed B-lymphoblastoid cell lines (B-LCL) and K562 cells as classical natu- ral killer (NK) cell targets served as controls. Fig 6 A demonstrates that F-Ara indeed increased the antigenicity of HMEC towards allogeneic PBMC at all E/T ratios tested.

The lack of specific lysis of K 562 and autologous effector B-LCL verified the in- volvement of MHC restricted cytotoxic T lymphocytes (CTL). In addition, lysis of ei- ther untreated or F-Ara treated HMEC could almost fully be blocked after coincuba- tion of these cells with the anti-MHC class | antibody w6/32 (Fig 6 A, « _). To further confirm that CD8+ CTL were responsible for the anti-endothelial cytotoxic activity,

PBMC were selected for CD8+ and CD4+ T cells (non-CD8 and non-CD4-depleted

PBMC, respectively) using magnetic bead separation with MACS'" bead kits. Purity of the preparations was > 93% in all cases with a complete absence of the other cell population (not shown). Separated T cells were stimulated with HMEC and IL-2 ex- actly as described for unselected PBMC (see above). As shown in Fig 6 B, lysis of F-

Ara-treated HMEC by CD8+ CTL was , again, significantly higher than that of control

HMEC. Furthermore, pretreatment of target HMEC with F-Ara and Defibrotide (F-

Ara+D) downregulated specific lysis even below control levels, suggesting that Defi- brotide also protects endothelial cells against the lysis of allogeneic effector lympho- cytes. HMEC stimulated CD4+ T cells did not show any signs of cytotoxic activity in this experimental setting (data not shown). Flow cytometric analyses of F-Ara versus

F-Ara+D treated HMEC resulted in a significant downregulation of MHC class | mole- cules by Defibrotide, suggesting that MHC class | expression is the critical element in regulating the cytotoxic response induced by F-Ara (data not shown).

Example 7

Anti-endothelial CTL display an T.1-like phenotype

To gain information about the nature of the anti-endothelial CTL, PBMC and CD8+ T cells were stimulated as given above, and supernatants were collected for the as- sessment of interferon gamma (IFN-y) and interleukin 4 (IL-4) using ELISA analyses.

As depicted in Tab 1, stimulation with HMEC and IL-2 obviously led to the outgrowth of Tc1-like T cells as could be told from the unique expression of IFN-y, whereas no

IL-4 was produced.

Example 8

F-Ara downregulates lysis of HMEC by allogeneic NK cells

Another interesting question was how F-Ara induced modulations of the MHC class expression affects the cytolytic response of natural killer (NK) cells against endothe- lial cells. PBMC from healthy individuals were negatively selected for NK cells (non-

NK cell depleted) and stimulated for 4 days with irradiated HMEC in the presence of

IL-2, as it was described for the experiment in Fig 6B. At day 4, HMEC as target cells : have either been left untreated or incubated with F-Ara (10 pg/mL) for 24 hours and subjected to a standard S1Cr release assay with the stimulated NK cells as effectors.

Fig 7 demonstrates that F-Ara significantly downregulated the allogenicity of HMEC towards NK cells. As a positive control for NK cell activity, lysis of MHC class | nega-

tive K 562 cells could be observed (Fig 7, « ). Pretreatment of F-Ara stimulated

HMEC with the anti-MHC class | antibody w6/32 completely abrogated the effect of

F-Ara and led to almost 100 % specific lysis of HMEC (Fig 7), suggesting that MHC class | on the surface of HMEC is, again, the critical switch for the regulation of the cytotoxic response of NK cells. The role of killer cell inhibitory receptors (KIR) that have been found to be negatively regulated by high expression levels of MHC class molecules®* might be responsible for the the decreased cytolytic response of NK cells. .

DISCUSSION

Clinical results with fludarabine containing reduced intensity conditioning (RIC) regi- mens obtained so far show a clear downregulation of conditioning-related toxicity without affecting immune reconstitution.” The incidence of acute GvHD in patients receiving RIC is comparable or even less than in those patients receiving the classi- cal conditioning regimen.?® However, reports on equally severe or even increased late effects like osteonecrosis,” pulmonal complications,” and more cases of chronic

GvHD arise.?® Despite its well documented immunosuppressive properties fludara- bine, in our study, has turned out to activate and damage endothelial and epithelial cells. This observation might, at least in part, explain the undesired clinical side ef- fects described above, since osteonecrosis is an expression of endothelial dysfunc- tion, and fludarabine appears to be toxic for alveolar epithelial cells. lt is interesting to note that the harmful effects of fludarabine on lung cells seem to be compartment- specific, as bronchial epithelial cells did not undergo apoptosis in response to this immunosuppressant. The fact that a keratinocyte cell line (HaCaT) was also sensitive to fludarabine suggest that it might also be involved in cutaneous disorders post

SCT. As the pathogenesis of late complications is multifactorial and might also be in- fluenced by increasing age of the SCT patients and the use of peripheral stem cells further evaluation in clinical analyses of pulmonal and dermatological complications is needed.

Since in many pre-transplant protocols fludarabine is used in combination with ioniz- . ing radiation it was important to test whether these two compounds would cooperate in affecting endothelial cells. Interestingly, we could not find any enhancement of ra- diation induced cell death by fludarabine or vice versa (data not shown). This sug-

gests differential mechanisms of how the apoptotic death signal is transfered to en- dothelial cells.

The precise mechanism how fludarabine induces apoptosis in endothelial and epithelial cells remains to be elucidated. It is likely that fludarabine — as a purin ana- logue -integrates into the DNA and thus causes mutations that lead to gene deletion like reported previously.®° It has also been suggested that fludarabine can cooperate with cytochrome c and apoptosis protein-activating factor-1 (APAF-1) in triggering the apoptotic caspase pathway.”

Fludarabine increases the allogenicity of endothelial cell targets for CD8+ T cells. In contrast, Fludarabine significantly downmodulates the endothelial lysis by allogeneic

NK cells. The MHC class | expression seems to be critical for the regulation of any of these immune responses, since a blockade of class | fully abrogated CTL lysis and tremendously upregulated lysis by NK cells. These opposing effects of fludarabine, taken together with the clinical observation that fludarabine shows less acute and equal or even more chronic toxicity than the classical conditioning regimen raises the speculation that NK cells and CTL might be active in different phases of GvHD pathophysiology, i.e. NK cells would primarily act in the earlier (suppressed by fluda- rabine), and CTL in the later phase (enhanced by fludarabine) post transplant.

With regard to the nature of the anti-endothelial CTL it is an interesting question whether these CTL are endothelial- or simply allo-specific. The existence of endothe- lial-specific effector lymphocytes has been described previously.?? In contrast to the

CTL we characterized as displaying a Tc1-like phenotype, many of the CTL clones reported show little, if any, IFN-y and unusually express CD40 ligand at rest what might enhance cytolytic activity. But these data do not rule out the existence of ad- ditional allogeneic CTL with a specificity for non-nematopoetic targets.

Defibrotide is a well tolerated drug successfully used for the treatment of veno- occlusive disease as one major hepatic complication post SCT.* In addition, there is an increasing number of pre-clinical and clinical reports showing its efficacy in treat- . ing ischemia/reperfusion injury and atherosclerosis, as well as recurrent thrombotic thrombocytopenic purpura.®** Defibrotide is known to act directly on endothelial : cells without further metabolism required®® and could, therefore, be used in our in vi- tro studies. Defibrotide fully protected endothelial and epithelial cells from fludarabine mediated apoptosis. Additional experimentation is needed to assess the precise mechanism of protection by which Defibrotide antagonizes fludarabine, but one can imagine a role for Defibrotide in an inhibition of DNA integration of fludarabine or the aforementioned caspase activation. Besides its anti-apoptotic effects, Defibrotide was able to downregulate anti-endothelial CTL responses by regulating MHC class expression. In contrast, Defibrotide did not affect the desirable anti-leukemic effect of fludarabine, as shown by the lack of protection of AML cells. Another important ob- servation was that Defibrotide could not block the fludarabine-mediated apoptosis of

PBMC. This suggests that the immunosuppressant effect of fludarabine mandatory for conditioning is not influenced by a co-treatment with defibrotide. it is of note that Defibrotide was not protective against radiation induced endothelial cell damage, suggesting its effect to be specific for fludarabine mediated cellular changes (data not shown).

Based on these results and with respect to its little, if any, side effects, we conclude from our study that Defibrotide is a good candidate used in combination with fludara- bine during conditioning prior to SCT, especially in patients at risk for VOD. Studies analyzing endothelial protection against further conditioning agents should help to clarify whether Defibrotide can be used as a broad protective agent.

REFERENCES

1. Holler E, Kolb HJ, Mdller A et al. Increased serum levels of tumor necrosis factor a precede major complications of bone mamow transplantation. Blood. 1990;75:1011-1016. 2. Antin JH, Ferrara JLM. Cytokine dysregulation and acute graft-versus-host dis- ease. Blood. 1992;80:2964-2968. 3. Ferrara JL, Levy R, Chao NJ. Pathophysiological mechanisms of acute graft-vs.- host disease. Biol Blood Marrow Transplant. 1999;5:347-356. 4. Xun CQ, Brown BA, Jennings CD, Henslee-Downey PJ, Thompson JS. Acute graft-versus-host-like diseases induced by transplantation of human activated natural killer cells into SCID mice. Transplantation. 1993;56:408-417. 5. Weiner RS, Bortin MM, Gale RP et al. Interstitial pneumonitis after bone marrow transplantation. Assessment of risk factors. Ann Intern Med. 1986;104:168-175. 6. Weiss MA. Novel treatment strategies in chronic lymphocytic leukemia. Curr On- col Rep. 2001;3:217-222. 7. Wasch R, Reisser S, Hahn J et al. Rapid achievement of complete donor chimer- ism and low regimen-related toxicity after reduced conditioning with fludarabine, carmustine, melphalan and allogeneic transplantation. Bone Marrow Transplant. 2000;26:24 3-250. 8. Carella AM, Champlin R, Slavin S, McSweeney P, Storb R. Mini-allografts: ongo- ing trials in humans. Bone Marrow Transplant. 2000;25:345-350. 9. Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marror transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hema- tologic diseases. Blood. 1998;91:756-763. 10. Holler E, Kolb HJ, Hiller E et al. Microangiopathy in patients on cyclosporine pro- phylaxis who developed acute graft-versus-host disease after HLA-identical bone marrow transplantation. Blood. 1989;73:2018-2024. 11.Eissner G, Kohlhuber F, Grell M et al. Critical involvement of transmembrane

TNF-a in endothelial programmed cell death mediated by ionizing radiation and : bacterial endotoxin. Blood. 1995;86:4184-4193. 12.Lindner H, Holler E., Ertl B et al. Peripheral blood mononuclear cells induce pro- grammed cell death in human endothelial cells and may prevent repair - role of cytokines. Blood. 1997,89:1931-1938.

13.Haimovitz-Friedman A, Balaban N, Mcloughlin M et al. Protein kinase CC mediates basic fibroblast growth factor protection of endothelial celis against radiation- induced apoptosis. Cancer Res. 1994;54:2591-2597. 14.Fuks Z, Persaud RS, Alfieri A et al. Bacic fibroblast growth factor protexcts endo- thelial cells against radiation-induced programmed cell death in vitro amd in vivo.

Cancer Res. 1994;54:2582-2590. 15.Eissner G, Lindner H, Behrends U et al. Influence of bacterial endotoxim on radia- tion-induced activation of human endothelial cells in vitro and in vivo, protective role of IL-10. Transplantation. 1996;62:819-827. 16.Lindner H, Holler E, Gerbitz A, Johnson JP, Bornkamm GW, Eissner G.. Influence of bacterial endotoxin on radiation-induced activation of human endothelial cells in vitro and in vivo: 2. IL-10 protects against transendothelial migration. Wransplan- tation. 1997,64:1370-1973. 17.Beelen DW, Haralambie E, Brandt H et al. Evidence that sustained growth sup- pression of intestinal anaerobic bacteria reduces the risk od acute graaft-versus- host disease after sibling marrow transplantation. Blood. 1992;80: 2668--2676. 18.Eissner G, Multhoff G, Holler E. Influence of bacterial endotoxin on the allogenic- ity of human endothelial cells. Bone Marrow Transplant. 1998;21:1286-1 287. 19.Ades EW, Candal FJ, Swerlick RA et al. HMEC-1: establishment of an immortal- ized human microvascular endothelial cell line. J Invest Dermatol. 1892;99:683- 690. 20.Cotter TG, Lennon SV, Glynn JM, Green DR. Microfilament-disruptirg agents prevent the formation of apoptotic bodies in tumor cells undergoing =apoptosis.

Cancer Res. 1992;52:997-1005. 21.Lee A, Whyte MK, Haslett C. Inhibition of apoptosis and prolongation of neutrophil functional longevity by inflammatory mediators. J Leukoc Biol. 1993;54:283-288. 22. Westphal JR, Tax WJ, Willems HW, Koene RA, Ruiter DJ, De-Waal R M. Acces- sory function of endothelial cells in anti-CD3-induced T-cell proliferaticon: syner- gism with monocytes. Scand J Immunol. 1992;35:449-457. 23.MacDonald HR, Engers HD, Cerrottini JC, Brunner KT. Generation of cytotoxic T lymphocytes in vitro. J Exp Med. 1974,;140:718-722. 24.Long E. Regulation of immune responses through inhibitory receptors. Annu Rev

Immunol. 1999;17:875-304.

25.Nagler A, Aker M, Or R et al. Low-intensity conditioning is sufficient to ensure en- graftment in matched unrelated bone marrow transplantation. Exp Hematol. 2001;29:362-370. 26.Michallet M, Bilger K, Garban F et al. Allogeneic hematopoietic stem-cell tran- plantation after nonmyeloablative preparative regimens: impact of pretransplanta- tion and posttransplantation factors on outcome. J Clin Oncol. 2001;19:3340- 3349. 27. Holler E, personal communication 28. Hildebrandt G, Bertz H, Mestan A et al. Analysis of pulmonary function after allo- geneic bone marrow trasplantation (BMT) or blood stem cell transplantation (PBSCT) using conditioning regimens with total body irradiation (TBI) and con- ventional intensity compared to regimens without TBI with reduced intensity [ab- stract]. Bone Marrow Transplant. 2001;27 (Suppl. 1):S216. 29.Bornhauser M, Thiede C, Schuler U et al. Dose-reduced conditioning for alloge- neic blood stem cell transplantation: durable engraftment without antithymocyte globulin. Bone Marrow Transplant. 2000;26:119-125. 30.Huang P, Siciliano MJ, Plunkett W. Gene deletion, a mechanism of induced mu- tation by arabinosyl nucleosides. Mutat Res. 1989;210:291-301. 31.Genini D, Budihardjo |, Plunkett W et al. Nucleotide requirements for the in vitro activation of the apoptosis protein-activating factor-1-mediated caspase pathway.

J Biol Chem. 2000;275:29-34. 32.Biederman BC, Pober JS. human vascular endothelial cells favor clonal expan- sion of unusual alloreactive CTL. J Immunol. 1999;162:7022-7030. 33. Briscoe DM, Alexander Al, Lichtman AH. Interactions between T lymphocytes and endothelial cells in allograft rejection. Curr Op Immunol. 1998;10:525-531. 34.Pegram AA, Kennedy LD. Prevention and treatemnt of veno-occlusive disease.

Ann Pharmacother. 2001,;35:935-942. 35.Rossini G, Pompilio G, Biglioli P et al. Protectant activity of defibrotide in cardio- plegia followed by idchemia/(repersusion injury in the isolated rat heart. J Card

Surg. 1999;14:334-341. 36.Rossini G, Berti F, Trento F et al. Defibrotide normalizes cardiovascular function hampered by established atherosclerosis in the rabbit. Thromb Res. 2000,97:29- 38.

37.Pogliani EM, Perseghin P, Parma M, Pioltelli P, Corneo G.

Defibrotide in recurrent thrombotic thrombocytopenic purpura.

Clin Appl Thromb Hemost. 2000;6:69-70. 38.San T, Moini H, Emerk K, Bilsel S.

Protective effect of defibrotide on perfusiors in- duced endothelial damage.

Throm Res. 2000;99:335-341. 39.Chopra R, Eaton JD, Grassi A et al.

Defibrotide for the treatment of hepatic veno- occlusive disease: results of the European compassionate-use study.

Br J Hiae- matol. 2000;111:1122-1129.

Claims (51)

1. Use of a protective oligodeoxyribonucleotide for the manufacture of a medica- ment for the treatment of a patient undergoing treatment with an immunosupres- sant.

2. Use of a protective oligodeoxyribonucleotide for the manufacture of a medica- ment for protecting epithelial and/or endothelial cells from the effects of an immu- nosuppressant.

3. Use of a protective oligodeoxyribonucleotide for the manufacture of a medica- oo ment for protecting epithelial and/or endothelial cells from apoptosis and/or acti- vation induced by the administration of an immunosuppressant.

4. Use according to claims 1-3 wherein the immunosuppressant is a nucleoside.

5. Use according to claims 1-3 wherein the immunosuppressant is selected from the groups comprising fludarabine, cyclophosphamide, BCNU, melphalan.

6. Use according to claims 1-3 wherein the immunosuppressant is fludarabine.

7. Use according to claims 1-3 wherein the protective oligodeoxyribonucleotide is defibrotide.

8. Use according to claims 1-7 wherein the step of administering the protective oli- godeoxyribonucleotide occurs concomitantly, simultaneously, after or before the administration of the immunosuppressant to the patient.

9. Use according to claim 8 wherein the step of administering the protective oligo- deoxyribonucleotide occurs after that of administering the immunosuppressant to . the patient.

10. Use according to claim 9 wherein the time delay between the step of administer- ing the protective oligodeoxyribonucleotide and that of administering the immu-

nosuppressant to the patient is from about one hour to about two weeks, prefera- bly from about two days to about seven days.

11. Use according to claim 8 wherein the step of administering the protective oligo- deoxyribonucleotide occurs before that of administering the immunosuppressant to the patient.

12. Use according to claim 11 wherein the time difference between the step of ad- ministering the protective oligodeoxyribonuclieotide and that of administering the immunosuppressant to the patient is from about one hour to about two weeks, preferably from about two hours to about two days.

13. Use according to claims 1-12 wherein the dose of defibrotide administered is chosen so as to reach a blood level from about 100 pg/mL to about 0.1 pg/mL, preferably from about 10 pg/mL to about 100 pg/mL.

14. Use according to claim 13 wherein the dose of defibrotide administered is chosen so as to reach a blood level of about 10 pg/mL.

15. Use according to claims 1-14 wherein the dose of defibrotide administered is from about 100 mg/kg body weight of the patient to about 0.01 mg/kg body weight, preferably from about 20 mg/kg body weight of the patient to about 0.1 mg/kg body weight.

16. Use according to claim 15 wherein the dose of defibrotide administered is from about 15 mg/kg body weight of the patient to about 1 mg/kg body weight, pref- erably about 12 mg/kg body weight of the patient.

17. Use according to any one of the preceding claims wherein the activation includes enhanced expression of I[CAM-1.

18. Use according to any one of the preceding claims wherein the treatment with an immunosupressant occurs during stem cell transplantation.

PCT/EPU3/05753

19. Use according to claim 18 wherein he stem cell transplantation is allogeneic . J stem cell transplantation.

20. A phamaceutical composition containing a therapeutically effective dose of an immunosuppressant and of a protective oligodeoxyribonucleotide.

21. A pharmaceutical composition acco-rding to claim 20 constituted by two different separately administrable formulatiors, one contzining the immunosuppressant and the other the protective cligode oxyribonuclectide.

22. A pharmaceutical composition acco rding to claim 20 as a combined preparstion for simultaneous, separate or sequential use.

23. A pharmaceutical composition acco rding to claims 20-22 wherein the immuno- suppressant is a nucleoside.

24. A pharmaceutical composition acco rding to claims 20-22 wherein the immuno- suppressant is selected from the groups comprising fludarabine, cyclophospha- mide, BCNU, melphalan.

25. A pharmaceutical composition acco rding to 20-22 wherein the immunosuppres- sant is fludarabine.

26. A pharmaceutical composition acco rding to 20-22 wherein the protective oligode- oxyribonucleotide is defibrotide.

27. A pharmaceutical composition acco rding to any one of the preceding claims characterized by further containing customary excipients and/or adjuvants.

28. A pharmaceutical composition acco rding to any one of the preceding claims ) characterized in that it is intravenou sly injectable. 28 CILEAN COPY

PCT/EPO3/05753

29. A substance or composition for use in a method for the treatment of a patient undergoing treatment with an immunosuppressant, said substance or composition comprising a protective oligodeoxyribonucleotide, and said method comprising administering said substance or composition.

30. A substance or composition for use in a method for protecting epithelial and/or endothelial cells from the effects of an immunosuppressant, said substance or composition comprising a protective oligodeoxyribonucleotide, and said method comprising administering said substance or composition.

31. A substance or composition for use in a method for protecting epithelial and/or endothelial cells from apoptosis and/or activation induced by the administration of an immunosuppressant, said substance or composition comprising a protective oligodeoxyribonucleotide, and said method comprising administering said substance or composition.

32. A substance or composition for use in a method of treatment according to claims 29-31 wherein the immunosuppressant is a nucleoside.

33. A substance or composition for use in a method of treatment according to claims 29-31 wherein the immunosuppressant is selected from the groups comprising fludarabine, cyclophosphamide, BCNU, melphalan. 29 AMENDED SHEET

{ PCT/EPO3/05753

34. A substance or composition for use in a method of treatment according to claims 29-331 wherein the immunosuppressant is fludarabine.

35. A substance or composition for use in a method of treatment according to claims 29-31 wherein the protective oligodeoxyribonucleotide is defibrotide.

36. A substance or composition for use in a method of treatment according to claims 29 -35 wherein the step of administering said substance or compositio n occurs concomitantly, simultaneously, after or before the administrattion of the immunosuppressant to the patient.

37. A substancce or composition for use in a method of treatment according to claim 36 wwherein the step of administering said substance or composition occurs after that of administering the immunosuppressant to the patient.

38. A substance or composition for use in a method of treatment according to claim 37 v-vherein the time delay between the step of administering said substance or composition and that of administering the immunosuppressant to the patieent is from about one hour to about two weeks, preferably from about two day to about seven days.

39. A substance or composition for use in a method of treatment according to claim 36 wsherein the step of administering said substance or composition AMENDED SHEET

{ PCT/EPO3/05753 occurs before that of administering the immunosuppressant to the patient.

40. A substance or composition for use in a method of treatment according to claim 39 wherein the time difference between the step of administering said substance or composition and that of administering the immunosuppressant to the patient is from about one hour to about two weeks, preferably for about two hours to about two days.

41. A substance or composition for use in a method of treatment according to claims 29 - 40 wherein the dose of defibrotide administered is chosen so as to reach a blood level from about 100 yg/mL to about 0.1 yg/mL, preferably from about 10 pg/mL to about 100 yg/mL.

42. A substance or composition for use in a method of treatment according to claim 41 wherein the dose of defibrotide administered is chosen so as to reach a blood level of about 10 pg/mL.

43. A substance or composition for use in a method of treatment according to claims 29-42 wherein the dose of defibrotide administered is from about 100 mg/kg body weight of the patient to about 0.01 mg/kg body weight, preferably from about 20 mg/kg body weight of the patient to about 0.1 mg/kg body weight. 31 AMENDED SHEET

+ ( PCT/EPO3/05753

44. A substance or composition for use in a method of treatment according to claim 43 wherein the dose of defibrotide administered is from about 15 m g/kg body weight of the patient to about 1mg/kg body weight, preferably about 12 mg/kg body weight of the patient.

45. A substance or composition for use in a method of treatment according to amy one of claims 29-44 wherein the activation includes enhanced expression of ICAM-1.

46. A substance or composition for use in a method of treatment according to amy one of claims 29-45 wherein the treatment with an immunosuppressant occurs during stem cell transplantation.

47. A substance or composition for use in a method of treatment according to cl.aim 46 wherein the stem cell transplantation is allogeneic stem cell transplantation.

48. Usse according to any one of claims 1-19, substantially as herein described amd illustrated. 49, A composition according to any one of claims 20-28, substantially as herein described and illustrated. 32 AMENDED SHEET

PCT/EPO3/05753

50. A substance or composition for use in a method of treatment according to any one of claims 29-47, substantially as herein described and illustrated.

51. A new use of a protective oligodeoxyribonucleotide, a new composition, or a substance or composition for a new use in a method of treatment, substantially as herein described. 33 AMENDED SHEET